BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Sandoz Takes Aim at AbbVie’s Humira with FDA Acceptance of Biosimilar Application

  Sandoz hopes its high-concentration formulation of an already greenlit biosimilar will be approved by the time AbbVie’s blockbuster drug Humira loses patent protection in the United States.

  July 21, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Discovery of Unique Cancer-Cloaking Collagen could Identify New Pancreatic Cancer Targets

  Researchers at MD Anderson Cancer Center have uncovered a new method in which some solid tumor cells are evading detection: the formation of their own type of collagen.

  July 21, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Job Trends

  Pfizer and Eikon Expand East Coast Presence with New York Facilities

  Pfizer is looking to strengthen its grip on mRNA research and development with a $470 million new facility, and Eikon is planning to open a 25,000 facility. Both will be based in New York.

  July 21, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Business

  BioSpace Movers & Shakers: National Cancer Institute, Evelo, Eagle, ROME & More

  Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week’s Movers & Shakers.

  July 21, 2022

   · 

  6 min read

   · 

  Alex Keown
• 

  Business

  Roche Ends Five Trials, Schinecker to Succeed Schwan as CEO (Updated)

  As Severin Schwan prepares to step aside from the day-to-day leadership of Roche, Thomas Schinecker is waiting in the wings to assume the company’s top leadership spot.

  July 21, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Research Roundup: Gut Disorders Linked to Alzheimer’s, ASOs Target Cystic Fibrosis & More

  According to a study, people with certain gut disorders may be at greater risk of Alzheimer’s disease, and researchers have discovered a potential use for ASOs against cystic fibrosis.

  July 21, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Policy

  Biogen Quietly Resolves Whistleblower Case for $900M

  The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors to favor its multiple sclerosis drugs over those of its competitors.

  July 21, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Assembly Bio, X4 Reprioritize Pipelines, Slash Headcounts

  Assembly Biosciences and X4 Pharmaceuticals have announced significant layoffs and reprioritization endeavors to let go of underperforming initiatives.

  July 21, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Freeline’s One Dose Gene Therapy could Transform Hemophilia B Treatment

  Freeline Therapeutics’ hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.

  July 21, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS
• 

  Drug Development

  “Imagine” a World without Daily Insulin Injections for Type 1 Diabetes

  In a recent interview with BioSpace, Imagine Pharma CEO Ngoc Thai shared the vast potential posed by a polypeptide called IMG-1 to treat Type 1 diabetes.

  July 21, 2022

   · 

  5 min read

   · 

  Hayley Shasteen